Adapted from Moreau et al. 2022
*del(17p), t(4;14) and/or t(14;16)
**≥1 PI, ≥1 IMiD and ≥1 anti-CD38 mAb
†≥2 PI, ≥2 IMiD and ≥1 anti-CD38 mAb
^Median follow up of 14.1 months
For further information regarding TECVAYLI including full indications, all adverse effects and data please refer to the Israeli MOH prescribing information: https://israeldrugs.health.gov.il/#!/byDrug
The data in this presentation is based on published clinical studies, please see references at the bottom of the slides/throughout the presentation.